肝素/血小板因子4抗体检测对肝素诱导的血小板减少症诊断的一致性有限:TORADI-HIT研究分析
这项前瞻性队列研究纳入10家三级医院1393例疑似肝素诱导的血小板减少症(HIT)患者,以肝素诱导的血小板活化(HIPA)试验为参考标准,比较三种肝素/血小板因子4抗体免疫检测方法的相关性。结果显示免疫检测间相关性弱(rs 0.53-0.65),HIT阳性119例(患病率8.5%),亚组分析未能解释检测间差异,作者提出需要标准化免疫检测。
要点
- 1393例疑似HIT患者中HIT阳性119例,患病率8.5%。
- 三种肝素/血小板因子4抗体免疫检测间相关性弱,rs为0.53-0.65。
- 性别、年龄、肝素暴露、血栓、心血管手术及ICU等因素未能解释检测间差异。
核心结论
- 广泛使用的肝素/血小板因子4抗体检测之间相关性弱,关键因素无法解释这种变异性,需要标准化免疫检测以提高可比性。
研究设计与样本
- 大型前瞻性队列研究,纳入10家参与的三级医院共1393例临床实践中疑似HIT的患者。
- HIT定义为肝素诱导的血小板活化(HIPA)试验阳性(洗涤血小板参考标准试验)。
- 采用三种免疫检测方法测定肝素/血小板因子4抗体:化学发光免疫检测、酶联免疫吸附试验和颗粒凝胶免疫检测。
主要发现
- 1393例患者中119例被分类为HIT阳性(患病率8.5%)。
- HIT患者的中位4Ts评分为5分(IQR 4-6),非HIT患者为3分(IQR 2-4)。
- 免疫检测之间的相关性弱,rs为0.53-0.65。
- 对z评分检测结果和亚组患者诊断优势比的进一步分析未能解释免疫检测之间的不一致性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Anecdotal reports suggest that the correlation between heparin/platelet factor 4 (PF4) antibody assays for the diagnosis of heparin-induced thrombocytopenia (HIT) is limited. OBJECTIVES: To investigate the correlation between widely used assays and examine possible factors contributing to variability. METHODS: This is a large, prospective cohort study with 10 participating tertiary care hospitals including 1393 patients with suspected HIT in clinical practice. HIT was defined by a positive heparin-induced platelet activation (HIPA) assay (washed platelet reference standard test). Three different immunoassays were used to measure heparin/PF4 antibodies: chemiluminescent immunoassay, enzyme-linked immunosorbent assay, and particle gel immunoassay. Various factors that could influence the assays were examined: sex (male or female), age (<65 years or ≥65 years), unfractionated heparin exposure, presence of thrombosis, cardiovascular surgery, and intensive care unit. Spearman's correlation coefficients were calculated. Z-scores and diagnostic odds ratios were determined in the aforementioned subgroups of patients. RESULTS: Among 1393 patients, 119 were classified as HIT-positive (prevalence, 8.5%). The median 4Ts score was 5 (IQR, 4-6) in patients with HIT compared with 3 (IQR, 2-4) in patients without HIT. Correlations (rs) between immunoassays were weak (0.53-0.65). Inconsistencies between immunoassays could not be explained by further analyses of z-scored test results and diagnostic odds ratios in subgroups of patients. CONCLUSION: The correlation between widely used heparin/PF4 antibody assays was weak, and key factors could not explain this variability. Standardization of immunoassays is requested to improve comparability.
引用
- Hammerer-Lercher A, Nilius H, Studt JD, et al. Limited concordance of heparin/platelet factor 4 antibody assays for the diagnosis of heparin-induced thrombocytopenia: an analysis of the TORADI-HIT study. J Thromb Haemost. 2023. PMID: 37247669. doi:10.1016/j.jtha.2023.05.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。